Role of primary surgery in advanced ovarian cancer

World Journal of Surgical Oncology

Volumn 2, Issue , 2004, Pages

  Münstedt, Karsten ^a   Franke, Folker E ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM DERIVATIVE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; GYNECOLOGIC SURGERY; HUMAN; LYMPHADENECTOMY; MEDICAL SPECIALIST; META ANALYSIS; METASTASIS; OVARY CANCER; PROGNOSIS; QUALITY CONTROL; REVIEW; SURGEON; SURGICAL TECHNIQUE; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 13844272109     PISSN: 14777819     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7819-2-32     Document Type: Review

References (91)

1. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000, 70:209-262.
2. Wittekind C, Meyer HJ, Bootz F: TNM-Klassifikation maligner Tumoren. Heidelberg, Springer 2003.
3. Ozols RF, Rubin SC, Thomas G, Robboy S: Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology Edited by: Hoskins WJ, Perez CA, Young RC. Philadelphia: Lippincott-Raven Publishers; 1997:919-986.
4. Winter-Roach B, Hooper L, Kitchener H: Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 2003, 13:395-404.
5. Brinkhuis M, Meijer GA, Baak JPA: An evaluation of prognostic factors in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1995, 63:115-124.
6. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999, 353:1207-1210.
7. Bell R, Petticrew M, Sheldon T: The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol 1998, 105:1136-1147.
8. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, Crayford TJ, Collins WP: Screening for early familial ovarian cancer with transvaginal ultrasonography and color blood flow imaging. BMJ 1993, 306:1025-1029.
9. van Nagell JR, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000, 77:350-356.
10. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR: Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997, 65:408-414.
11. Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP: Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003, 21:378-385.
12. Petricoin EF, Ardekani AM, Hitt BA, Levine BA, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
13. Aure JC, Hoeg K, Kolstad P: Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971, 37:1-9.
14. Griffith CT, Fuller AF: Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 1978, 58:131-142.
15. Michel G, De Iaco P, Castaigne D, el-Hassan MJ, Lobreglio R, Lhomme C, Rey A, Duvillard P: Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1997, 18: -15.
16. Griffiths CT: Surgery at the time of diagnosis of ovarian cancer. In: Management of ovarian cancer Edited by: Blackledge G, Chan KK. London: Butterworth; 1986:60.
17. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727-1733.
18. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
19. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vegote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Tropé C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindwall B, Bacon M, Birt A, Anderson JE, Zee B, Paul J, Baron B, Pecorelli S: Randomized intergroup trial of ciplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92:699-708.
20. Kehoe ST, Luesley DM, Ward K, Chan KK: In vivo evidence of increased malignant cell proliferation following surgery in ovarian cancer. Int J Gynecol Cancer 1995, 5:121-127.
21. Shaw M, Wolfe C, Raju KS, Papadopoulos A: National guidance on gynecological cancer management: an audit of gynecological cancer services and management in the South East of England. Eur J Gynaecol Oncol 2003, 24:246-250.
22. Münstedt K, von Georgi R, Zygmunt M, Misselwitz B, Stillger B, Künzel W: Shortcomings and deficits in surgical treatment of gynecological cancers: a German problem only? Gynecol Oncol 2002, 86:337-343.
23. Münstedt K, von Georgi R, Misselwitz B, Zygmunt M, Stillger R, Künzel W: Centralizing surgery for gynecologic oncology - a strategy assuring better quality treatment? Gynecol Oncol 2003, 89:4-8.
24. Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000, 342: 878-86.
25. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342:1887-1892.
26. Vergote I: Controversies in surgery in ovarian cancer - what is its real role? Eur J Cancer 2003, 39(Suppl 1): 15-125.
27. Arzouman DA, Caccavale RJ, Sisler GE, Lewis RJ: Endobag. Ann Thorac Surg 1993, 55:1266-1267.
28. Childers JM, Nasseri A, Survit EA: Laparoscopic management of suspicious adnexal masses. Am J Obstet Gynecol 1996, 175: 451-1459.
29. Abu-Rustum NR, Sonoda Y, Chi DS, Teoman H, Dizon DS, Venkatraman E, Barakat RR: The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol 2003, 90:431-434.
30. Volz J, Koster S, Scaeff B: Laparoscopic management of gynaecologic malignancies, time to hesitate. Gynecol Endosc 1997, 84:358-361.
31. Eisenkop SM, Spirtos, Friedman RL, Lin W-CM, Pisani AL, Perticucci S: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003, 90: 90-396.
32. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Torri V, Mangioni C: The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998, 9:1097-1101.
33. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer - Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003, 95:113-125.
34. Simojoki M, Santala M, Vuopala S, Kauppila A: The prognostic value of peritoneal cytology in ovarian cancer. Eur J Gynaecol Oncol 1999, 20:357-360.
35. Young RC, Decker DG, Wharton JT, Piver MS, Sindelair WF, Edwards BK, Smith JP: Staging laparotomy in early ovarian cancer. JAMA 1983, 250:3072-3061.
36. Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-Pearson DL: Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 1992, 80:949-953.
37. Moore DH: Primary surgical management of early epithelial ovarian carcinoma. In: Rubin SC, Sutton GP. Ovarian cancer Edited by: Rubin SC, Sutton GP. Philadelphia: Lippincott Williams & Wilkins; 2001:201-218.
38. Arbeitsgemeinschaft für Gynäkologische Onkologie: Leitlinien Maligne Ovarialtumoren. Frauenarzt 2000, 41: 09-915.
39. Eisenkop SM, Spirtos NM: The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol 2001, 82:143-149.
40. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhomme C, Duvillard P, Castaigne D: Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003, 197:198-205.
41. Allen DG, Coulter J: Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease. Aust N Z J Obstet Gynaecol 1999, 39:420-424.
42. Kikkawa F, Ishikawa H, Tamakoshi K, Suganuma N, Mizuno K, Kawai M, Arii Y, Tamakoshi A, Kuzuya K, Tomoda Y: Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer. J Surg Oncol 1995, 60:227-231.
43. Yokoyama Y, Sakamoto T, Sato S, Saizo Y: Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol 1999, 20:361-366.
44. Saygili U, Guclu S, Uslu T, Erten O, Ture S, Demir N: Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study. J Surg Oncol 2002, 81:132-137.
45. Parazzini F, Valsecchi G, Bolis G, Guarnerio P, Reina S, Polverino G, Silvestri D: Pelvic and paraortic lymph node status in advanced ovarian cancer and survival. Gyncol Oncol 1999, 74: -11.
46. Favalli G, Odicino F, Torri V, Pecorelli S: Early stage ovarian cancer: the Italian contribution to clinical research. An update. Int J Gynecol Cancer 2001, 11(Suppl 1):12-19.
47. di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, di Re E: Systematic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastasis. Gynecol Oncol 1996, 62:360-365.
48. Wheeler JE: Pathology of malignant ovarian epithelial tumors and miscellaneous and rare ovarian and paraovarian neoplasms. In: Ovarian cancer Edited by: Rubin SC, Sutton GP. Philadelphia: Lippincott Williams & Wilkins; 2001:99-134.
49. Breitenecker G, Bartl W, Schreiber V: Die prognostische Bedeutung morphologischer Parameter bei malignen Ovarialtumoren. Pathologe 1983, 4:29-40.
50. Meigs JV: Tumors of the female pelvic organs. New York, McMillan 1934.
51. Munnell E: The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol 1968, 100:790-805.
52. Hunter RW, Alexander ND, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992, 166:504-511.
53. Eisenkop SM, Spirtos NM: What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001, 82:489-497.
54. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1994, 170:974-980.
55. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
56. von Georgi R, Franke FE, Münstedt K: The influence of tumorbiology, surgery, and postoperative therapy on patient prognosis in advanced ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol 2003, 111:189-196.
57. Kehoe S, Powell J, Wilson S, Woodman C: The influence of the operating surgeons's specialisation on patient survival in ovarian carcinoma. Br J Cancer 1994, 70:1014-1017.
58. Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A: National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993, 72: 663-3670.
59. Zollinger RM, Ellison EC, Fabri PJ Johnson J, Sparks J, Carey LC: Primary peptide ulceration of the jejunum associated with islet cell tumors. Twenty-five year appraisal. Ann Surg 1980, 120: 22-430.
60. Merlo A, Müller-Brand J, Mäcke HR: Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir Suppl 2003, 88:83-91.
61. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003, 197:29-37.
62. Kondo K, Monden Y: Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003, 76:878-884.
63. Woodman C, Baghdady A, Collins S, Clyma JA: What changes in the organization of cancer services will improve the outcome for women with ovarian cancer? Br J Obstet Gynaecol 1997, 104: 35-139.
64. Grilli R, Minozzi S, Tinazzi A, Labianca R, Sheldon TA, Liberati A: Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. Ann Oncol 1998, 9:365-374.
65. Junor EJ, Hole DJ, Gillis CR: Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994, 70363-370.
66. Junor EJ, Hole DJ, McNulty L, Mason M, Young J: Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999, 106:1130-1136.
67. Harlan LC, Clegg LX, Trimble EL: Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003, 21:3488-3494.
68. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL: A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002, 84:36-42.
69. Gershenson DM, McGuire WP: Ovarian cancer: controversies in management. New York: Churchill Livingstone 1998.
70. Rubin SC, Sutton GP: Ovarian cancer. Philadelphia: Lippincott Williams & Wilkins 2001.
71. Hirsch HA, Käser O, Iklé FA: Atlas der gynäkologischen Operationen. Stuttgart, New York: Thieme 1999:349-351.
72. Kuhn W, Hamann U, Kimmig R, Rehbock J, Schmalfeldt B, Schwoerer M: Operative Therapie. In: Tumorzentrum München (Kuhn W). Maligne Ovarialtumoren - Empfehlungen zur Diagnostik, Therapie und Nachsorge. München, Bern, Wien, New York: Zuckschwerdt 2001:4-31.
73. Tokuhashi Y, Kikkawa F, Ishikawa H, Tamakoshi K, Hattori S, Matsuzawa K, Inoue T, Suganuma N, Tomoda Y: Distribution of platinum in human gynecologic tissues and pelvic lymph nodes after administration of cisplatin. Gynecol Obstet Invest 1997, 44:270-274.
74. Gehrig PA, Van Le L, Fowler WC: The role of omentectomy during the surgical staging of uterine serous carcinoma. Int J Gynecol Cancer 2003, 13:212-215.
75. Sendt W, Amberg R, Schoffel U, Hassan A, von Specht BU, Farthmann EH: Local inflammatory peritoneal response to operative trauma: studies on cell activity, cytokine expression, and adhesion molecules. Eur J Surg 1999, 165:1024-1030.
76. Salzer H, Denison U, Breitenecker G, Lax G, Kapp K: Ovarialkarzinom. [http://www.aco.at/manual/ovar/kap_12.html]. [accessed October 11th, 2003]
77. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasable and maximizes survival in patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 1998, 69: 03-108.
78. Cavina E, Goletti O, Molea N, Buccianti P, Chiarugi M, Boni G, Lazzeri E, Bianchi R: Trocar site tumor recurrences. May pneumoperitoneum be responsible? Surg Endosc 1998, 12: 294-1299.
79. Gryspeerdt S, Clabout L, Van Hoe L, Berteloot P, Vergote IB: Intraperitoneal contrast material combined with CT for detection of peritoneal metastases in ovarian cancer. Eur J Gynaecol Oncol 1998, 19:434-437.
80. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995, 332: 29-634.
81. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH: A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 2002, 21:201a. [Abstract 802]
82. van der Burg MEL, Vergote I: The role of interval debulking surgery in ovarian cancer. Curr Oncol Rep 2003, 5: 73-481.
83. Münstedt K, Hering Kv, Prittwitz J, Zygmunt M, Franke FE, Vahrson H: Verletzungen des therapieplans und des chemotherapieprotokolls beim ovarialkarzinom - Gründe und Konsequenzen. Zentralbl Gynäkol 1998, 120:534-539.
84. Münstedt K, Kovacic M, Zygmunt M, von Georgi R: Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol 2003, 23: 37-843.
85. Gaducci A, Cosio S, Fanucchi A, Manganelli L, Conte PF, Cristofani R, Genazzani AR: Is pretreatment hemoglobin level a predictor of complete response to salvage chemotherapy for recurrent platinum-pretreated ovarian carcinoma? Eur J Gynaecol Oncol 2003, 24:405-410.
86. Blohmer U, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimmig R, Dressler, Kentenich, Kohls A, Lichtenegger W, for the NOGGOAGO-Intergroup: 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer. Proc Am Soc Clin Oncol 2003, 22:447. [Abstract 1798]
87. Wietzke-Braun P, Ritzel U, Nolte W, Leonhardt U, Armbrust T, Koc M, Funke M, Grabbe E, Ramadori G: Ultrasound-guided laser interstitial thermo therapy for treatment of non-resectable primary and secondary liver tumours - a feasibility study. Ultrasound Med 2003, 24:107-112.
88. Berek JS, Bertelsen K, du Bois A, Leonhardt U, Armbrust T, Koc M, Funke M, Grabbe F, Ramadori G: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999, 10(Suppl 1):87-92.
89. Konazawa K, Suzuki T, Tokashiki M: The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol 1999, 73:237-241.
90. Lück HJ, du Bois A, Weber B, Pfisterer J, Goupil A, Kuhn W, Barats JC, Blohmer J, Mousseau M, Schröder W, Meier W, Möbus V, Richter B, for the AGO-GINECO Intergroup: The integration of anthracyclines in the treatment of advanced ovarian cancer. Int J Gynecol Cancer 2001, 11(Suppl 1):34-38.
91. Pfisterer J, Lortholary A, Kimmig R, Weber B, Du Bois A, Bourgeoi H, Wagner U, Coudert B, Meier W, Costa S, for the AGO and GINECO Study Groups: Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-TOP) in firstline treatment of ovarian cancer FIGO stages IIB - IV. Interim results of a Gynecologic Cancer Intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol 2003, 22:446. [Abstract 1793]